AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
The American Journal of Managed Care

Inhaled COPD Medications Associated With Negative Postoperative Outcomes in Patients With Early-Stage NSCLC

Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and ...
Healthline

COPD: Symptoms and Patient Groups

COPD symptoms vary depending on the amount of lung damage that has occurred due to inhaled substances, most commonly smoking. Symptoms are usually slow to develop and often don’t appear until there’s ...
Healio

Misdiagnosis of heart failure possible in patients with COPD

Please provide your email address to receive an email when new articles are posted on . Systemic inflammation and endothelial dysfunction are some mechanisms linking COPD to heart failure with ...
Nasdaq

Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary ...
Benzinga.com

ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment

), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions. The Food and Drug Administration (FDA) recently cleared ResMed's home ...